Takhzyro 150 MG
Ended Awarded
- Contract number
- 36C24526N0104
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $36,984
Award facts
- Contract value 100% obligated
- $36,984.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Brooks, KY 40109, USA
Award details come from SAM.gov/FPDS.
About this award
Takeda Pharmaceuticals America Inc. was awarded a $36,984.28 firm fixed-price delivery order for TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. The contract, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, is a child order under Takeda's broader Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.04 million. The award was issued without a set-aside designation, reflecting the specialized and single-source nature of this critical medication. Performance will occur in Brooks, Kentucky, and the contract is funded through Veterans Integrated Service Network 5, a component of the Department of Veterans Affairs responsible for delivering healthcare services to veterans.
This delivery order supports the VA's mission to provide advanced pharmaceutical treatments to veterans with rare genetic disorders. TAKHZYRO is specifically indicated for hereditary angioedema management and represents the type of highly specialized medication that Takeda delivers to federal healthcare systems through its established GSA Pharmaceuticals and Drugs Schedule contract vehicle. The minimal gap between award and completion dates suggests this is a routine replenishment order fulfilling existing demand within the VA's pharmacy benefit program, enabling continuity of care for veterans requiring this critical therapeutic agent.
Quick answers
Who was awarded contract 36C24526N0104?
36C24526N0104 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on October 16, 2025.
How much is contract 36C24526N0104 worth?
The government has obligated $36,984 on 36C24526N0104.
Is contract 36C24526N0104 an order under another contract?
Yes. 36C24526N0104 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0104 competed?
The extent of competition for 36C24526N0104 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award